ASM Microbe is back and scheduled to take place in person. The Seegene Technologies team will be set up at Booth 419, so come by to learn about our molecular diagnostic solutions that can simultaneously detect multiple targets with high accuracy…
Congress approved the first National DNA Day in April 2003 to celebrate both the completion of the Human Genome Project and the 50th anniversary of the discovery of the double-helix structure of DNA. Here are some fun facts related to…
Image by Arek Socha from Pixabay The recently reported Omicron variant of SARS-CoV-2 has a 69-70del mutation in the S-gene (which codes for the spike protein). This implies that the S-gene is not detected on PCR tests. The World Health…
CONTACT SEEGENE TECHNOLOGIES The new assay identifies positive COVID-19 cases and distinguishes between Alpha, Beta, Gamma, Delta, Omicron and its Stealth version. Published on: PR Newswire Seegene Inc. (KQ 096530), South Korea's leading molecular diagnostics company, today unveiled another series…
To Our Valued Seegene Customer, The World Health Organization has identified the Omicron variant (B.1.1.529) as the latest strain of the SARS-CoV-2 virus to be designated as a Variant of Concern. As the first cases are emerging in the US,…
Image by Alexandra_Koch from Pixabay On Friday, November 26, the Omicron variant of SARS-CoV-2, the agent behind COVID-19 was classified as a variant of concern by the World Health Organization (WHO) after reports of its detection and genetic sequence were released…
Published on: PR Newswire The Allplex™ SARS-CoV-2 Master Assay can simultaneously detect the wild-type coronavirus and the Omicron variant in a single test tube Seegene will support countries in need of diagnostics to help slow Omicron's spread Seegene Inc. (KQ…
Image by Luisella Planeta Leoni from Pixabay As temperatures begin to fall in many parts of the U.S., the onset of cold and flu season is present in the minds of many Americans. Many of us make it out unscathed, but when a…
Exploring New Horizons in Infectious Diseases Seegene Technologies will be exhibiting at the SCASM 2021 In-person Annual Meeting. If you're at the event, stop by our Booth #114 to learn more about how our molecular assays and automated solutions can help…
Image by Thiago Lazarino from Pixabay Like all RNA viruses, SARS-CoV-2 is prone to mutations—adaptive changes that can alter a virus’ pathogenic potential and other characteristics. These mutations can create distinct variants of the virus, adding complexity to what has…
Published on: PR Newswire Seegene unveils its first fully automated MDx system, STARlet-AIOS: All-in-One System at the 2021 AACC held in the Atlanta, GA, United States AIOS is the MDx system that integrates Seegene's liquid handler and real-time PCR instruments. Seegene MDx system…
Image by fernando zhiminaicela from Pixabay With the introduction of vaccines and an abundance of testing options, the initial frenzied rush to get tested for COVID-19 has subsided in the US. However, confusion about the different types of tests and…
An exciting opportunity to join a world leader in molecular diagnostics! Seegene Inc. is looking for candidates with a Ph.D. in Biological Sciences related fields (or equivalent job experience) to join the R&D team at our Headquarters in Seoul, South…
By N. Mueller A year and a half into the SARS coronavirus (SARS-CoV-2) pandemic and we are still playing catchup. Just as COVID testing ramped up, the UK, South African (S.A.), and Brazilian (Bz) variants appeared. Now we hear about…
According to the COVID tracking project, over 355 million tests have been performed in the United States as of March 2021. The tests have played a crucial role on the frontlines of the COVID-19 pandemic, up until today. However, the…
It’s been one year since Seegene produced a complete respiratory diagnostic test that has taken the uncertainty out of differentiating COVID-19 infection from other respiratory illnesses Fast Response In January 2020, before a single patient with SARS-CoV-2 virus had been…
Published on: PR Newswire Seegene launches new multiplex PCR test capable of screening six SARS-CoV-2 variants including the Delta and Delta Plus variants attributable for a recent surge in global COVID-19 cases. The new CE-IVD marked variants detection kit to…
Seegene will be exhibiting at the upcoming 2021 AACC Annual Scientific Meeting & Clinical Lab Expo. Visit our Booth# 2953 to learn more about our Molecular assays and automation solutions for your laboratory. Date: September 26-30, 2021 Where: Georgia World Congress Center in Atlanta, Georgia…
Date: August 24-26, 2021 Where: Grand Hyatt Washington, D.C. and Virtual Register Now: https://www.nextgenerationdx.com/
Date: June 8-9, 2021 Where: National Harbor, MD Register here: https://jointcbrn.dsigroup.org/ Description: Stop by Seegene Technologies' exhibit at the '9th Annual Joint Civil & DoD CBRN Symposium'. Join us as we will be showcasing our latest innovations- Mobile Labs and…
Topic: RT PCR testing for SARS-CoV-2 Individual CT values, automation, and future detection of Covid-19 variants Time and Date: Wednesday, April 28, 2021, 1pm–2pm ET Speakers: Glen Hansen, MDMedical Director of Microbiology and MolecularDiagnostics, Hennepin County Medical Center Valerie Ng,…
Published on: PR Newswire Seegene can produce 300,000 variant diagnostic test kits, capable of testing 30 million people every month SEOUL, Korea (April 12, 2021) – Seegene Inc. (KQ 096530), a biotechnology company specializing in molecular diagnostics, announced today that…
Topic: Survival in the times of COVID-19 Time: 12:45 - 1:00 pm EDT Date: March 25, 2021 To view the presentation, register here: https://endeavor.swoogo.com/mlo_forum/registration Speakers: Valerie Ng, PhD, MD - Chair, Laboratory Medicine & Pathology, Alameda Health System (AHS) Linda…
Published on: BUSINESS WIRE Real-time test differentiates influenza A & B, RSV and COVID-19 SEOUL, South Korea (March 1, 2021)— Seegene Inc., (KQ096530), a biotechnology company specializing in molecular diagnostics, has submitted its Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay to the U.S. Food…
Published on: PR Newswire - Seegene’s new product filters COVID-19 and variants during primary PCR testing in 1 hr 55 min- Seegene’s proprietary high multiplex technology enables detection of 10 different targets- S. Korean firm to research additional versions of…
Published on: PR Newswire A new study shows that the less-invasive saliva test for COVID-19 gives just as accurate results as those of the nasopharyngeal specimen. A research team at the Department of Laboratory Medicine at Kangwon National University School…
Published on: PR Newswire SEEGENE LAUNCHES FIRST MULTIPLEX TEST TO IDENTIFY COVID-19 MUTANTS THE MANUFACTURER OF COVID-19 TESTS CONTINUOUSLY FOLLOWS THE SPREAD OF THE VARIANTS THE KOREAN COMPANY UNDERTAKES TO COOPERATE WITH GOVERNMENTS SEOUL , South Korea, Feb. 4, 2021…
SEOUL, South Korea, Sept. 8, 2020 /PRNewswire/ -- Seegene, Inc. introduced a single tube real-time RT-PCR assay, Allplex™ SARS-CoV-2/FluA/FluB/RSV Assay, which simultaneously detects and differentiates Flu A, Flu B, RSV A/B, and three different target genes of COVID-19 (S gene, RdRP gene…
Published on: 매일경제 한국경제 PR Newswire 조선일보 SEOUL, Korea, Apr 22, 2020 - Seegene, Inc. announced that U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for its Allplex™ 2019-nCoV Assay, a Real-time RT-PCR test for SARS-CoV-2, the novel coronavirus responsible…
Published on: PR Newswire ABC News Seegene, Inc., the leading multiplex diagnostic assay developer, today announced that the company has exported over 10 million tests of Allplex™ 2019-nCoV Assay to over 60 countries, which accounts for a significant portion of globally…
2019 American Society for Microbiology Microbe Conference: Booth #1062 Published on: PR Newswire SEOUL, South Korea, June 21, 2019 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered in South Korea, announced that it has completed the FDA registration…
Published on: PR Newswire SEOUL, South Korea, Nov. 26, 2018 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR assays, announced that multi-site clinical trials for measuring clinical performance on screening the drug resistance of Enterobacteriaceae with the Allplex™ Entero-DR assay have…
Published on: PR Newswire SEOUL, South Korea, Sept. 19, 2018 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, today announced its proprietary technology, "MuCT™". This is a real-time PCR based data acquiring and analyzing technology that increases its…
Published on: PR Newswire Korea Biomedical Review SEOUL, South Korea, April 17, 2018 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies, announced that it will attend the 28th European Congress of Clinical Microbiology and Infectious Diseases ("ECCMID 2018") taking…
Published on: PR Newswire THE INVESTOR SEOUL, South Korea, Jan. 3, 2018 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies headquartered in South Korea, announced today that, utilizing a newly created artificial intelligence ("AI") based assay development system, the company succeeded in…
Published on: PR Newswire SEOUL, South Korea, Sept. 26, 2017 /PRNewswire/ -- Seegene, a world's leading developer of multiplex molecular technologies and assays, announced that it has signed a Memorandum of Understanding (MOU) with Hamilton Company, a global leader in the design and…
Published on: scientifictechnologynews Seoul, Korea, 2017/08/31 – Seegene, the world’s leading developer of multiplex molecular technologies and assays, announced that it has recently signed collaborative contracts with 30 general hospitals and reference laboratories across 15 nations for the co-development of…
Published on: PR Newswire SEOUL, South Korea, July 26, 2017 /PRNewswire/ -- Seegene Inc. (096530.KQ), the world's leading developer of multiplex molecular diagnostics technologies and assays, is to present its unique Seegene Random Access System (the "System") at the 69th AACC Annual Clinical Lab…
Published on: PR Newswire SEOUL, South Korea, May 22, 2017 /PRNewswire/ -- Seegene Inc. (096530.KQ), the world's leading developer of multiplex molecular diagnostics technologies and assays, today announced that it has entered into a new strategic collaboration relationship with Thermo Fisher Scientific…
Published on: PR Newswire SYS-CON MEDIA SEOUL, South Korea, April 26, 2017 /PRNewswire/ -- Seegene Inc. (096530.KQ), the leading developer of multiplex PCR technologies, announced that it is entering into more innovative and powerful business realm by developing the Second-generation Real-time…
Published on: PR Newswire NEWS PROVIDED BY Seegene Feb 14, 2017, 08:00 ET EOUL, South Korea, Feb. 14, 2017 /PRNewswire/ -- Seegene Inc. (096530.KQ), a leading developer of multiplex PCR technologies today announced that it has developed a new software technology that…
Published on: PR Newswire GenomeWeb Seoul, Korea, November 4, 2016 --- Seegene Inc. (096530.KQ) today announced it has entered into a worldwide collaboration agreement with Hologic (Nasdaq: HOLX) to develop and supply high multiplex real-time PCR reagents for the Hologic Panther Fusion™…
Published on: PR Newswire Pressemitteilung lavanguardia 共同通信PRワイヤー (プレスリリース) HiNet 新聞社群 中华网 ThaiPR.net (ข่าวประชาสัมพันธ์) LeLézard.com foodqualitynews Customized assay design that dramatically reduces development time and cost Looking for potential local strategic partners in molecular diagnostics SEOUL, South Korea, Aug 2, 2016 - Seegene, Inc.(096530KQ), a leading developer of…
Published on: PR Newswire Jun 08, 2016 - Introducing a new SG oligo system which significantly saves assay development time and cost- Driving standardization of the molecular diagnostics technology with a new Universal SG Fluorescence oligo system and optimized real-time…
Published on: BUSINESS WIRE Mar 07, 2016 Newly established innovation division at Seegene Technologies will deliver customized assays of increased complexity while maintaining sensitivity, specificity, and cost-effectiveness for U.S. market Seegene Technologies, Inc., a wholly-owned subsidiary of Seegene, Inc. (096530.…
Published on GenomeWeb MarketWatch RTT News Seegene and BD Form Worldwide Collaboration to Develop Multiplex Molecular Diagnostic Assays Seoul, Korea, and Baltimore, MD, September 14, 2015 --- Seegene Inc. (096530.KQ) and BD Life Sciences, a segment of BD (Becton, Dickinson and Company)…
Published on: GenomeWeb Nasdaq streetinsider Seoul, Korea, and Hilden, Germany, July 8, 2015 --- Seegene Inc. (096530.KQ), today announced that it has entered into aworldwide collaboration agreement with QIAGEN N.V. (NASDAQ: QGEN; Frankfurt Prime Standard: QIA)to develop and supply molecular diagnostic assay. Under the…
Published on: GenomeWeb Seegene Establishes U.S. Subsidiary Seegene Technologies Inc. to Drive Growth in the U.S. and Global Molecular Diagnostics Market CONCORD, CA and SEOUL, KOREA--(Marketwired - Apr 7, 2015) - Seegene Inc. (KOSDAQ: 096530), a leading developer of multiplex PCR…